Retatrutide (LY3437943) has become one of the most studied synthetic peptides in current metabolic research. As a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it offers researchers a tool for investigating multi-pathway metabolic signaling that single or dual agonists cannot replicate. This overview covers retatrutide’s structure, mechanism of action, published clinical trial